Home › Breast Cancer › Florida › Plantation
Breast Cancer clinical trials in Plantation, FL
14 studies for Breast Cancer are looking for participants at sites in and around Plantation (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RecruitingPhase 3
- Miami Cancer Institute, Plantation
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Plantation
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- Miami Cancer Institute at Plantation, Plantation
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Miami Cancer Institute at Plantation, Plantation
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- University of Miami-SCCC-Plantation, Plantation
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RecruitingPhase 2
- Miami Cancer Institute - Plantation (MCIP), Plantation
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RecruitingPhase 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RecruitingPhase 3
- Miami Cancer Institute Plantation, Plantation
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RecruitingPhase 3
- BRCR Medical Center, Inc- Internal Medicine, Plantation
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecruitingPhase 2
- Miami Cancer Institute at Baptist Health, Plantation
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- BRCR Global, Plantation
- Florida Clinical Trials Group, Plantation
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- BRCR global, Plantation
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
RecruitingObservational study
- Baptist Cancer Care - Plantation, Plantation
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA111 studies
- Nashville, TN80 studies
- Los Angeles, CA72 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Plantation
- Non-Small Cell Lung Cancer16 studies
- Lupus7 studies
- Cancer (all types)7 studies
- Lung Cancer7 studies
- Rheumatoid Arthritis6 studies
- Metastatic Cancer6 studies
- Colorectal Cancer5 studies
- Psoriatic Arthritis5 studies
- Prostate Cancer5 studies
- Head and Neck Squamous Cell Carcinoma4 studies
- Multiple Myeloma4 studies
- Melanoma4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.